Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making - Takeaways - MDSpire

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

  • By

  • Eva Compérat

  • Gunhild von Amsberg

  • Lynda Corrigan

  • Stephen P. Finn

  • Glen Kristiansen

  • Angelo Minucci

  • David Olmos

  • Guilhem Roubaud

  • July 1, 2026

  • 0 min

Share

  • 1

    Nearly 25% of metastatic prostate cancer patients have homologous recombination repair pathway mutations, including BRCA1/BRCA2 alterations.

  • 2

    BRCA mutations in prostate cancer are linked to poorer prognosis and increased sensitivity to targeted therapies like PARP inhibitors.

  • 3

    Early testing for HRR and BRCA mutations is essential but not routinely implemented due to barriers such as unequal access and unclear guidelines.

  • 4

    The European Association of Urology recommends somatic or germline testing for HRR alterations in metastatic prostate cancer patients.

  • 5

    Implementing clear testing pathways can improve equity and access to genetic testing for prostate cancer across different healthcare settings.

Original Source(s)

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

  • by Eva Compérat, Gunhild von Amsberg, Lynda Corrigan, Stephen P. Finn, Glen Kristiansen, Angelo Minucci, David Olmos, Guilhem Roubaud

  • July 1, 2026

Related Content

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target

Prognostic value of initial recurrence pattern for post-recurrence survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells